AN2 Therapeutics, Inc.

ANTXReported to SECin USCIK 0001880438Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 17. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 17
Form 4 lines at AN2 Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Trenor Cameron C. IIIChief Medical OfficerAwardnothing paid233,333 sharesSep 16, 2026Trenor Cameron C. IIIChief Medical Officernothing paidAward · Sep 16Award233,333Sep 16, 2026
Trenor Cameron C. IIIChief Medical OfficerAwardnothing paid116,667 sharesSep 16, 2026Trenor Cameron C. IIIChief Medical Officernothing paidAward · Sep 16Award116,667Sep 16, 2026
Readnour Robin Shane—Open-market sell$3,524585 sharesSep 11, 2026Readnour Robin Shane$3,524Sell · Sep 11Open-market sell585Sep 11, 2026
Readnour Robin Shane—Open-market sell$3,151523 sharesSep 11, 2026Readnour Robin Shane$3,151Sell · Sep 11Open-market sell523Sep 11, 2026
Readnour Robin Shane—Open-market sell$31,8615,294 sharesSep 8, 2026Readnour Robin Shane$31,861Sell · Sep 8Open-market sell5,294Sep 8, 2026